Shots: The expanded program offers access to any branded BMS’s therapies for free, including its most widely prescribed therapies and those prescribed via telehealth services Patients can reach to BMS’ […]readmore
Tags : Existing
Shots: The collaboration will evaluate RNAi therapeutics targeting three host factors required for SARS-CoV-2 infection, including ACE2 and TMPRSS2. The third target is expected to emerge from Vir’s ongoing genomics […]readmore
Shots: The companies collaborate to develop and commercialize BPN14770 for AD, Fragile X syndrome and other indications marked by cognitive and memory deficits. Shionogi has increased its equity investment in […]readmore
Shots: Fibrocor to receive upfront, option exercise fee, milestones and royalties on sales of the product. Galapagos to receive an exclusive option to in-license up to 4 targets, out of […]readmore
Shots: Athenex to receive $30M up front, ~$170M milestones and royalties on sales of licensed products in China, Hong Kong and Macao. Xiangxue to get exclusive license to develop & […]readmore
Shots: As per the first agreement, Ardelyx to receive $10M for research and is eligible to receive ~10.5M upfront and up to $500M as development & commercialization milestone and will […]readmore
Shots: Editas to receive $70M up front, milestone and royalty payments for each therapy developed by Celgene and will develop genome editing tool for which Celgene has right to opt-in […]readmore
Shots: Leo Pharma(Leo) will select the targets and MorphoSys will recognize lead molecules using peptide technology platform. Leo Pharma will either develop the lead molecules or use them to design […]readmore